汇宇制药：公司研发的依托泊苷注射液、氟尿嘧啶注射液获得美国FDA批准

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) has received approval from the U.S. FDA for its new drug applications (NDA) for Etoposide Injection and Fluorouracil Injection, enabling the company to sell products in the U.S. market [1] Group 1 - The approval marks a significant milestone for the company, allowing it to expand its sales in the U.S. market [1] - This development strengthens the company's product supply chain and enriches its product portfolio [1] - The approval lays a solid foundation for the sustainable development of the company in international markets [1]